Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …
Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …
individuals, their families and caregivers, and healthcare systems. Although AD can be …
Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light
Background and Objectives To evaluate whether plasma biomarkers of amyloid
(Aβ42/Aβ40), tau (p-tau181 and p-tau231), and neuroaxonal injury (neurofilament light …
(Aβ42/Aβ40), tau (p-tau181 and p-tau231), and neuroaxonal injury (neurofilament light …
Blood-based biomarkers for Alzheimer's disease diagnosis and progression: an overview
A Varesi, A Carrara, VG Pires, V Floris, E Pierella… - Cells, 2022 - mdpi.com
Alzheimer's Disease (AD) is a progressive neurodegenerative disease characterized by
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances
Discovery and development of clinically useful biomarkers for Alzheimer's disease (AD) and
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …
Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts
H Cai, Y Pang, X Fu, Z Ren, L Jia - Nature Communications, 2023 - nature.com
Plasma amyloid-β (Aβ) 42, phosphorylated tau (p-tau) 181, and neurofilament light chain
(NfL) are promising biomarkers of Alzheimer's disease (AD). However, whether these …
(NfL) are promising biomarkers of Alzheimer's disease (AD). However, whether these …
Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease
Background Blood phosphorylated tau (p-tau) forms are promising Alzheimer's disease (AD)
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …
Challenges in the practical implementation of blood biomarkers for Alzheimer's disease
M Schöll, IMW Verberk, M Del Campo… - The Lancet Healthy …, 2024 - thelancet.com
Blood biomarkers have emerged as accessible, cost-effective, and highly promising tools for
advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal …
advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal …
Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients …
Introduction Plasma neurofilament light chain (NfL) is a potential biomarker for
neurodegeneration in Alzheimer's disease (AD), ischemic stroke, and non‐dementia cohorts …
neurodegeneration in Alzheimer's disease (AD), ischemic stroke, and non‐dementia cohorts …
Truncated Tau caused by intron retention is enriched in Alzheimer's disease cortex and exhibits altered biochemical properties
ZK Ngian, YY Tan, CT Choo, WQ Lin… - Proceedings of the …, 2022 - National Acad Sciences
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β plaques and
Tau tangles in brain tissues. Recent studies indicate that aberrant splicing and increased …
Tau tangles in brain tissues. Recent studies indicate that aberrant splicing and increased …